

Assessing the Risk Factors of Patients with Non-ST-Segment Elevation Myocardial Infarction

VERONICA GHEORMAN¹, VENERA CRISTINA DINESCU², MICHAEL SCHENKER³, DENISE RAMONA MALIN⁴,
MIOARA DESDEMONA STEPAN⁵, ELENA CATALINA BICA⁵, OANA CRICIOTOIU⁶, DIANA STANCA⁶, ADRIAN MITA⁷,
SORIN NICOLAE DINESCU^{8*}, MANUELA IULIANA DRAGOMIR⁹, FLORIN-CRISTIAN TAPU¹⁰, MARIA FORTOFOIU¹¹,
FLORIN MARIUS ROMANESCU¹², MARIUS BICA¹³, VICTOR GHEORMAN¹⁴

¹University of Medicine and Pharmacy of Craiova, Cardiology Department, 2 PetruRares Str., 200349, Craiova, Romania

²University of Medicine and Pharmacy of Craiova, Health Promotion and Occupational Medicine Department, 2 Petru RaresStr., 200349, Craiova, Romania

³University of Medicine and Pharmacy of Craiova, Oncology Department, 2 PetruRaresStr., 200349, Craiova, Romania

⁴University of Medicine and Pharmacy of Craiova, Otorhinolaryngology Department, 99 CaleaBucuresti Str., 200473, Craiova, Romania

⁵University of Medicine and Pharmacy of Craiova, Department of Pediatrics, 2 PetruRaresStr., 200349, Craiova, Romania

⁶University of Medicine and Pharmacy of Craiova, Neurology Department, Neuropsychiatry Hospital of Craiova, 99 CaleaBucuresti Str., 200473, Craiova, Romania

⁷University of Medicine and Pharmacy of Craiova, Internal Medicine Department, Filantropia Hospital of Craiova, 1Filantropiei Str., 200143, Craiova, Romania

⁸University of Medicine and Pharmacy of Craiova, Epidemiology and Primary Health Care Department, 2 PetruRares Str., 200349, Craiova, Romania

⁹University of Medicine and Pharmacy of Craiova, Department of Public Health and Healthcare Management, 2 PetruRares Str., 200349, Craiova, Romania

¹⁰University of Medicine and Pharmacy of Craiova, Cardiology Department, Filantropia Hospital of Craiova, 1Filantropiei Str., 200143, Craiova, Romania

¹¹University of Medicine and Pharmacy of Craiova, Department of Emergency Medicine and First Aid, 2 PetruRares Str., 200349, Craiova, Romania

¹²University of Medicine and Pharmacy of Craiova, Department of Physiology, 2 PetruRares Str., 200349, Craiova, Romania

¹³University of Medicine and Pharmacy of Craiova, Surgery Department, 2 PetruRares Str., 200349, Craiova, Romania

¹⁴University of Medicine and Pharmacy of Craiova, Psychiatry Department, Neuropsychiatry Hospital of Craiova, 24 AleeaPotelu Str., 200473, Craiova, Romania

Cardiovascular risk management decisions are based on the full profile of cardiovascular risk factors. It is important not only the number of cardiovascular risk factors accumulated by a patient but the magnitude of each factor, both being proportional to cardiovascular risk.

Keywords: acute coronary syndromes, non-ST-segment elevation myocardial infarction, risk factors.

The prevalence of cardiovascular disease is decreasing in developed countries, but increasing in developing countries due to increased longevity, urbanization and lifestyle changes.

Cardiovascular diseases are responsible for approximately 30% of worldwide deaths each year. 80% of these occur in low or middle income areas, which encapsulate for about 85% of the world's population [1-2].

Acute coronary syndromes along with stable angina are the major clinical manifestation of ischemic heart disease. Unstable angina and non-ST-segment elevation myocardial infarction are included in acute coronary syndrome without ST segment elevation, non-ST-segment elevation myocardial infarction being differentiated from unstable angina by the presence of cardiomyocyte necrosis as evidenced by increased serum levels of cardiac biomarkers.

Data from national registries show that the annual incidence of hospitalizations for acute coronary syndromes without ST segment elevation is 3/1000 inhabitants. The incidence of the disease varies widely across European countries, with the highest rates of incidence and mortality being recorded in Central and Eastern Europe [3].

Although the in-hospital mortality of patients with ST-segment elevation infarction is higher than those with non-ST segment elevation infarction (7% vs. 5%), long-term it becomes similar (12% vs. 13%) [4-5]. This is due to the patients profile with acute coronary syndromes without ST segment elevation who are older, have a higher prevalence of cardiovascular risk factors and comorbidities, or frequently history of myocardial infarction or myocardial revascularization compared to patients with ST segment elevation infarction [6].

Experimental part

The aim of the study

The study was aimed to determine the prevalence of non-ST-segment elevation myocardial infarction and to correlate with the presence of risk factors, depending on age.

In our study we included patients admitted to the County Hospital of Craiova, Cardiology Department, between January 2018 and January 2019.

The patients have fulfilled the criteria and wanted to participate in our study after obtaining informed consent.

*email: dinescus73@yahoo.com, Phone: 0745632232

Authors have equally contributed to the paper and they should be regarded as main authors.

	FEMALE		MALE		Total	
Age	N	%	N	%	N	%
40-49	2	1.49%	9	5.26%	11	3.60%
50-59	14	10.45%	30	17.54%	44	14.40%
60-69	22	16.42%	58	33.92%	80	26.20%
70-79	60	44.78%	41	23.98%	101	33.10%
>79	36	26.87%	33	19.30%	69	22.60%
Total	134		171		305	

Table 1
DISTRIBUTION BY AGE GROUP

The inclusion criteria were:

-Patients with history compatible with myocardial infarction

-Positive cardiac markers (Trop T/Trop I,CK-MB)

The exclusion criteria were patients with stable and unstable angina.

Results and discussion

Our study included 305 patients with NSTEMI whose mean age was 70.62 ± 11.05 years CI 95% (69.28 - 71.77) confirming the presence of non-ST-segment elevation myocardial infarction at older age [7-11] being more than 5 years old for women (73.36 ± 10.05 years) than for males (68.3 ± 11.32 years).

Asubstudy of INTERHEART showed that women make the first acute myocardial infarction 9 years later than men. [12] The risk factors associated with the risk of similar acute myocardial infarction between men and women are dyslipidemia, current smoking, obesity, diet and psychosocial factors [13-15]. The younger age of acute myocardial infarction in men was explained by higher levels of plasma lipids and smoking before age 60, especially as smoking is more common in males all over the world [16-17].

The number of men with NSTEMI was higher ($N = 171$; 56.10%) than women ($N = 134$; 43.90%). This result is confirmed from literature data, in the middle-aged population the risk of ischemic heart disease is 2-5 times higher in males than in women [18,19].

A total of 171 men (56.1%) and 134 women (43.9%) were included in our study, the gender ratio being (M / W) of 1.28, the slight predominance of males being due to the higher frequency of non-ST-segment elevation infarction among them. The lot was balanced in terms of urban areas 52.13% ($N=159$) and in rural areas 47.87 % ($N=146$).

Distribution by age group revealed a higher frequency in the seventh decade of the patients ($N = 101$, 33.1%). Over 83% of the population affected by coronary artery disease is over 65 years of age. In both sexes, the risk of ischemic coronary artery disease increases with age, one explanation lies in the fact that most cardiovascular risk factors have a higher prevalence in the elderly [20-24] (table 1).

Non-ST-segment elevation myocardial infarction was 3.5 times more common in men aged 40-49 years ($N =$

29; 5.26%) than women of the same age ($N = 2$; 1.49%) and nearly 2 times higher in subjects aged 50-59 years ($N = 30$; 17.54% vs. $N = 14$; 10.45%). The risk of NSTEMI was double in men aged less than 65 years compared to women ($RR = 2.33$, 95% CI 1.52 to 3.57, $p < 0.001$).

Smoking is a major risk factor for the myocardial infarction, including passive smoking being likely to increase cardiovascular risk. [25-29] Cardiovascular risk is even higher as the beginning of smoking occurs before the age of 15 [30].

A quarter of the subjects of the group ($N = 80$) were exposed to the effects of smoking, with the prevalence of smoking being 26.23%. Of these, 39 (12.8%) of patients were smokers and 41 (13.4%) were former smokers.

The prevalence of smoking was strongly influenced by age. The patients with 40-49 years old 72.73% ($N = 8$) were exposed to active smoking, half of them 36.36% ($N = 4$) were smokers at the time of study. Almost 70% ($N = 31$) of patients in the 50-59 age group were exposed to smoking, of whom 40.91% ($N = 18$) were smokers and 29.55% ($N = 13$) were former smokers. In contrast to the younger patients, in the elderly patients with non-ST-segment elevation myocardial infarction the prevalence was much lower, 15% ($N = 12$) at 60-69 years old, 1.98% ($N = 2$) in those aged 70-79 years 4.35% ($N = 3$). The risk for smokers under the age of 65 was 4 times higher than those over 65 years of age ($RR = 4.36$; 95% CI = 2.53-7.50; $P < 0.0001$).

The age-stratified risk reveals the impact of smoking in young patients with non-ST-segment elevation myocardial infarction, this risk is the highest in those patients of 40-49 years old ($RR = 7.04$; 95% CI = 4.08-12.15; $P < 0.0001$) and those aged 50-59 years $RR = 6.31$; 95% CI = 3.96 to 10.03; $P < 0.0001$). It was less or insignificant in those patients over this age group, and probably other risk factors such as biological and cardiovascular degeneration age-specific, as well as the cumulative effect of comorbidities may influence the risk (fig. 1).

Obesity is a major cardiovascular risk factor with prevalence in developed countries, especially due to environmental and social factors, diet and sedentary [31-34]. Obesity is also common in low socioeconomic populations associating and psychosocial risk factors [35].

Nearly half of patients with non-ST-segment elevation myocardial infarction had also obesity ($N = 138$), women ($N = 69$; 51.49%) being more frequently affected by obesity




Fig. 1 . The age-stratified risk in patients with non-ST-segment elevation myocardial infarction




Fig. 2. Percentage distribution of cases by degree of hypertension




Fig. 3.

than men ($N = 69$; 40.35%), the risk being higher at the first category ($RR = 1.28$; 95% $CI = 1.02-1.63$; $P = 0.0491$).

Hypertension is one of the most important causes of cardiovascular death, contributing to about half of global cardiovascular mortality [36]. In the INTERHEART study, hypertension contributed to cardiovascular risk by 18% of the assignment population risk [12].

High blood pressure (HBP) is the most characteristic feature of non-ST-segment elevation myocardial infarction patients, 262 patients being hypertensive (85.9%), both sexes being similarly affected by 83.0% of men and 89.6% of women.

Age plays an important role as a modulator of the increase in hypertension prevalence. In patients aged 40-49 years, 72.73% were affected by hypertension, as compared to those over the age of 50 years whose high blood pressure prevalence increased to over 80%, and those over the age of 75 years had high blood pressure prevalence to nearly 90%. Moreover, with age worsening high blood pressure occurs with the transition to higher degrees of hypertension (fig. 2, 3).

An analysis of the Copenhagen Heart Study, showed that diabetics have a high risk of acute myocardial infarction 2-3 times higher, independent of other cardiovascular risk factors [37] it is proven that the overall mortality of diabetes is comparable to those with a history of acute myocardial infarction, so that the NCEP ratio from 2002 included diabetes as the equivalent of high-risk ischemic heart disease [38-44].

The prevalence of diabetes in patients with non-ST-segment-elevation myocardial infarction was 34.1% ($N = 105$), being similar in both sexes 35.07% (47/134) in women and 33.92% (58/171), with no significant differences ($p = 0.3$) with the exception of a lower prevalence in the 40-49 age group, at which diabetes was

identified at 27.27% compared to the 50-59 age group (40.91%).

There was a higher prevalence of diabetes in non-ST-segment elevation myocardial infarction patients with high blood pressure, 37.8% (99/262) than those with NSTEMI without high blood pressure - diabetes prevalence was 14% (6/37). The risk of diabetes in hypertension cases is nearly 3 times higher than in cases without hypertension ($RR = 2.71$; 95% $CI = 1.27-5.78$; $P = 0.01$).

Epidemiological studies (Framingham study, Multiple Risk Factor Intervention Trial (MRFIT), Atherosclerosis Risk in Communities (ARIC)) revealed a direct relationship between total cholesterol serum and cardiovascular morbidity and mortality [45]. Cardiovascular risk increases by 2-3% for every percentage increase in total cholesterol.

Dyslipidemia ($N = 150$) was associated with half of the patients with non-ST-segment elevation myocardial infarction, which was more common in females (53%) than in males (45.61). The younger patients were more frequently affected by dyslipidemia, the prevalence being higher ($p = 0.01$), confirming the tendency to decrease the prevalence of dyslipidemias in NSTEMI ($r^2 = 0.96$). This highlights the effect of association of dyslipidemia in younger subjects probably related to its underdiagnosed and neglect (fig. 4).

The risk of dyslipidemia at younger age was 2.5 times higher than in the elderly (79 years), decreasing as the elderly progressed (table 2).

Stroke was identified in the medical history of 46 non-ST-segment elevation myocardial infarction cases, with its prevalence of 15.1%, higher in women (17.16) than in males (13.45%), difference without statistical significance ($p = 0.54$). The most affected age group was 60-69 years ($N = 16$; 20%), being more common ($P < 0.0001$) in NSTEMI




Fig. 4.

Table 2
RISK OF ASSOCIATION OF DYSLIPIDEMIA BY AGE GROUP

	Risk	95%IC	P
40-49	2.45	1.59 to 3.79	P = 0.0001
50-59	1.84	1.22 to 2.77	P = 0.0034
60-69	1.72	1.18 to 2.53	P = 0.0053
70-79	1.37	0.89 to 1.99	P = 0.1534




Fig. 5

Codes Y	DA	NU	Total		DA
40-49	4	7	11	40-49	36.36%
50-59	18	26	44	50-59	40.91%
60-69	38	42	80	60-69	47.50%
70-79	68	33	101	70-79	67.33%
>79	47	22	69	>79	68.12%
	176	129	305		
Chi-square	16.071				
DF	4				
Significance level	P = 0.0029				
Contingency coefficient	0.224				

Table 3

cases over 65 years of age (16.51%), comparative with those under 65 (11.49%).

More than half (57.7%) of the NSTEMI cases also associated the chronic heart failure, which was diagnosed in 176 cases. Chronic heart failure was more common in females (N = 86; 64.18%) than in males (N = 90; 52.63%), the risk of chronic heart failure association in NSTEMI women was 1.22 times higher than for men (RR = 1.22, 95% CI 1.01-1.475, P = 0.0411).

Chronic heart failure was more common in 70-79 year old (N = 33; 67.33%) and over 79 years (N = 22; 68.12%), age-increasing being an important factor in increasing chronic heart failure prevalence ($r^2 = 0.92$). In NSTEMI

patients over 65 years old (63.3%), the risk of chronic heart failure association was nearly 1.5 times higher (RR = 1.449; 95% CI 1.12-1.88; P = 0.005) than in cases under 65 years old (43.38%) (fig. 5).

Over 60% (N = 179) of non-ST-segment elevation myocardial infarction cases presented left ventricular ejection fraction with values below 50%. Men showed values below 50% more frequent (N = 105, 67.31%) than women (N = 74; 59.68%) and left ventricular ejection fraction deterioration was more pronounced in the elderly (73.03% in the age group 70-79 years) compared to younger age groups (where left ventricular ejection fraction was found less than 50% in the 40-49 age group - N = 5;

Table 4

Codes X	LVEF-CLS	
<50	179	63.90%
>50	101	36.10%
Total	280	100.0%
Chi-square	21.175	
DF	1	
Significance level	P < 0.0001	

Codes X	LVEF-CLS				
Codes Y	SEX				
	Codes X				
Codes Y	<50	>50	Total	<50	>50
F	74	50	124	59.68%	46.91%
M	105	51	156	67.31%	31.66%
	179	101	280		
	-63.90%	-36.10%			
Chi-square	1.429				
DF	1				
Significance level	P = 0.2319				
Contingency coefficient	0.071				

45.45%). Age over 65 increased by 1.3 times more the risk of left ventricular ejection fraction deterioration to below 50% (RR = 1.29, 95% CI = 1.03-1.61, P = 0.0281) (table 4).

Hospitalization days

Non-ST-segment elevation myocardial infarction cases required an average of 8.16 ± 4.39 hospitalization days (95% CI = 7.66 - 8.65). More than half of the NSTEMI were hospitalized for less than one week (N = 164, 54.5%) and only 23 cases (7.6%) required hospitalizations longer than two weeks.

Age has correlated with the number of days of hospitalization (Pearson correlation coefficient $r = 0.22$; 95% CI $r = 0.11-0.32$; P = 0.0002). Patients aged 40-49 had the shortest period of hospitalization at 6.91 ± 3.91 days, compared to elderly patients with median hospitalization days of 8.55 ± 4.57 in those aged 70 -79 years and over 9 days in those over 79 years (9.35 ± 4.3 days).

The high prevalence of high blood pressure in the general population and in specially in our study group (86.1%) makes it statistically difficult to correctly identify the role of high blood pressure in modulation of the hospitalization period ($p = 0.54$). In high blood pressure cases the mean of hospitalization days was 8.22 ± 4.24 and in those without HBP was 7.76 ± 5.29 days. The impact on hospitalization is better validated by the calculation of mean of hospitalization days depending on the degree of HBP that was under 7 days for hypertension grade 1 and 2 and 8.35 ± 4.22 days for hypertension grade 3 ($p < 0.01$). The association of chronic heart failure with non-ST-segment elevation myocardial infarction ($p = 0.01$) increases the number of hospitalization days to 8.713 ± 4.7 days compared to non-chronic heart failure patients (7.4 ± 3.82 days). The left ventricle ejection fraction deterioration less than 50% has the same effect, increasing by 1.5 days more ($p = 0.01$) the average number of hospitalization days (8.57 ± 4.4 days).

Conclusions

We considered that long-term follow-up must include lifestyle changing methods, risk factor correction and secondary prevention. It should be considered and implemented in all cases a cardiovascular recovery physical exercise program in stable patients, stopping

smoking and diet changes. Hypertension, dyslipidemia and diabetes mellitus should be diagnosed and treated with care and promptness.

Abbreviations

NSTEMI: non-ST-segment elevation myocardial infarction

LVEF: left ventricle ejection fraction

HBP: high blood pressure

References

1. RAMACHANDRAN S., BENJAMIN J., SULLIVAN M. The Burden of increasing worldwide cardiovascular disease. The Heart - Hurst's, 12 -th Edition, chapter 2, 2008:17-40.
2. LOZANO R., NAGHAVI M., FOREMAN K. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010 : A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095.
3. BASSAND JP, HAMM CW., ARDISSINO D., BOERSMA E., BUDAJ A., FERNANDEZ-AVILES F., FOX KA., HASDAID., OHMAN EM., WALLENTIN L., WIJNS W. Task force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non- ST-segment elevation acute coronary syndromes. Eur Heart J.2007 Jul;28(13):1598-660.Epub 2007 Jun14.
4. SAVONITTO S., ARDISSINO D., GRANGER CB., MORANDO G., PRANDO MD., MAFRICI A., CAVALLINI C., MELANDRI G., THOMPSON TD., VAHANIAN A., OHMAN EM., CALIFF RM., VAN DER WERFF F., TOPOL EJ. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999;281:707-713.
5. VOLMINK JA., NEWTON JN., HICKS NR., SLEIGHT P., FOWLER GH., NEIL HA. Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. The Oxford Myocardial Infarction Incidence Study Group. Heart 1998;80:40-44.
6. ROFFI M., PATRONO C., COLLET JP., MUELLER C., VALGIMIGLI M., ANDREOTTI F. et al; 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC), Eur Heart J, 2016 Jan 14;37(3):267-315.
7. KYTO V, SIPILA J, RAUTAVA P. Association of age and gender with risk for non-ST-elevation myocardial infarction. Eur J Prev Cardiol. 2015 Aug;22(8):1003-8. doi: 10.1177/2047487314539434. Epub 2014 Jun 9;

8. GIMBEL M. E. AND TEN BERG J. M. Management of elderly patients with a non-ST-segment-elevation acute coronary syndrome. *Neth Heart J*. 2017 Jul; 25(7-8): 409-415;
9. TRASCA, S.P., FLORESCU, C., DINESCU, V.C., PUIU, I., DINESCU, S.N., TUDORASCU, D.R., BICA, C., VASILE, R.C., ROMANESCU, F.M., BUNESCU, M.G., CIOATERA, N., GOANTA, E.V. The assesment of Percutaneous Coronary Angioplasty versus Coronary artery Bypass Grafting in Treatment of Left Main Coronary Artery Disease. *Rev. Chim. (Bucharest)*, **69**, no.12, 2018, p.3600-3604.
10. DINESCU, V.C., PUIU, I., DINESCU, S.N., TUDORASCU, D.N., BICA, E.C., VASILE, R.C., BUNESCU, M.G., ROMANESCU, F.M., CIOATERA, N., ROTARU, L.T., MUSTAFA, E.R., FLORESCU, F., Early Predictive Biochemical Electrocardiographic and Echocardiographic Markers for Cardiac Damage in Patients with Pulmonic Silicosis. *Rev Chim (Bucharest)*, **70**, no.1, 2019, p.63-68.
11. CALBOREAN, V., CIOBANU, D., MIREA, S.C., GALCEAVA, O., GHEORMAN, V., PADUREANU, V., FORTOFOIU, C.M., FORTOFOIU, M., MITA, A., DINESCU, S.N., MISCOCI, S.A., DINESCU, V.C. Benefit of Cardiac Resynchronization Therapy in Patients with Heart Failure. *Rev. Chim. (Bucharest)*, **69**, no. 9, 2018, p.2461-2464.
12. ANAND SS., ISLAM S., ROSENGREN A. et al. Risk factors for myocardial infarction in women and men: insight from the INTERHEART study, *Eur Heart J* 2008;29(7):932-940.
13. VLADU, I. M., RADU, L., GIRGAVU, S.R., BALEANU, V., CLENCIU, D., ENE, C.G., SOCEA, B., MAZEN, E., CRISTEA, O. M. MOTA, M., TENEA COJAN, T.S., An Easy Way to Detect Cardiovascular Risk , *Rev. Chim. (Bucharest)* **69**, no.11, 2018, p. 4229-4232
14. RADU, L., CARSOTE, M., GHEORGHISAN GALATEANU, A.A. PREDA, S.A., CALBOREAN, V., STANESCU, R., GHEORMAN, V., ALBULESCU, D.M., Blood Parathyrin and Mineral Metabolism Dynamics - A clinical analyze, *Rev. Chim. (Bucharest)*, **69**, no. 10, 2018 , p. 2754-2758.
15. TENEA COJAN, T.S., RADU, L., DAVITOIU, D., VLADU, I.M., BALEANU, V.D. CLENCIU, D., ENE, C.G., SOCEA, B., The Importance of the Chemical Composition of Synthetic Nets Used in Repair of Parietal Defects, *Rev. Chim. (Bucharest)* **69**, no. 10, 2018, p. 2677-2681
16. DRAGOMIR LP, MARGARITESCU C., FLORESCU A., OLIMID AD., DRAGOMIR M., POPESCU MR. The immunoexpression of EGFR and Her2/neu in oral squamous carcinoma. *Rom J Morphol Embryol*.2012;53(3):597-601.
17. T. S. TENEA COJAN, A. MACOVEI, I PAUN, A I COSTIN, C V GEORGESCU, C. C. GEORGESCU, I. M. VLADU, C. G. ENE, L. RADU, Assessment of hormonal receptor immunoexpression and Her2 status in invasive breast cancer after conservative and radical surgery, *Rom J Morphol Embryol* 2018, 59(3):763772
18. SHAW LJ., BAIREY MERZ CN., PEPINE CJ et al. Insight from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation(WISE) Study. Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. *J Am Coll Cardiol* 2006; 47(Suppl.3):S4-S20.
19. CALBOREAN, V., GHEORMAN, V., CONSTANTIN, C. ISTRATOIAE, O. Venous Thromboembolism Secondary to Adult-Onset Still's Disease: a Case Report, *Journal of Cardiovascular Emergencies*, 2018, 4, nr.2, p.101-105.
20. CALBOREAN, V. GHEORMAN, V., DINESCU, S.N., STANCA, D., GALCEAVA, O., FORTOFOIU, M., MITA, A., MIHAIOVICI, A.R., MISCOCI, S.A., BALEANU, V.D., DINESCU, V.C., Arrhythmia Risk in Patients with Chronic Hepatic Disease. *Rev. Chim (Bucharest)* **69**, no. 11, 2018, p. 4237-4240 (3337-3340).
21. V. CALBOREAN, I. UDRISTOIU, A. D. DOCEA, M. C. HODOROG, S. N. DINESCU, O. CRICIOTOIU, D. STANCA, A. MITA, D. V. DAVITOIU, V. D. BALEANU, F. M. ROMANESCU, M. BICA, C. S. MIREA, V. C. DINESCU. Evaluation of Echocardiographic Parameters in Patients with Rhythm Disorders Associated with Chronic Hepatic Disease. *Rev Chim (Bucharest)* **70**, no. 2, 2019, p. 659-662.
22. CORICI, O. A., TANASIE, C.A., ALEXANDRU, D.O., FLORESCU, C.M., COMANESCU, M.V., KAMAL, C., TENEA-COJAN, T.S., IANCAU, M., DINESCU, S.N. A morpho-functional study using PEP/LVET ratio and global longitudinal strain in patients with dilated cardiomyopathy. *Rom J Morphol Embryol*;2018,59(1):93-103.
23. PASALEGA M., MIREA C., VILCEA ID., VASILE I., PLESEA IE., CALOTA E., MESINA C., PARVANESCU H., BALUTA M. Parietal abdominal endometriosis following Cesarean section. *Romanian Journal of Morphology and Embriology*, vol 52, pag 503-508, supplement 1, 2011.
24. V. GHEORMAN, V. C. DINESCU, O. CRICIOTOIU, D. STANCA, V. CALBOREAN, A. MITA, A. MISCOCI, D. V. DAVITOIU, V. D. BALEANU, R-M. NEDELCUTA, S. N. DINESCU, A. L. DIJMARESCU, D-I. VOICULESCU, I. UDRISTOIU. Clinical and Biochemical Changes Induced by Alcohol at the Patients with Mental Illness. *Rev. Chim. (Bucharest)*, **70**, no. 4, 2019, p.1406-1410.
25. TEO KK., OUNPUU S., HAWKEN S., et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. *Lancet* 2006; 368: 647-58.
26. E. AMZOIU, M. AMZOIU, M. MUNTEANU, S. POPESCU, O. M. CRISTEA, R. SARBU Physicochemical parameters used for the study of antibacterial activity of benzimidazole derivatives *Journal of Science and Arts*. Year 19, no. 1 (46), pp. 177-184, 2019.
27. V.D. BALEANU, D.V. CONSTANTIN, B. SOCEA et al. Use of synthetic protetic materials in surgical abdominal defects. *Rev. Chim. (Bucharest)* **69**, no.7, 2018, p. 1740-1743.
28. CALBOREAN, V., GHEORMAN, V., AL NAMAT, R., CAZACU, I. M., VARJU, P., GEDE, N., STREBA, T.C., VERE, C.C., GHEONEA, D.I., GHEORMAN, V., LUNGULESCU, C., LUNGULESCU, C., V. The Association Between Stress Level and Laboratory Parameters, Sex, Age and Stage Disease in Patients with Digestive and Bronchopulmonary Neoplasms, *Rev. Chim. (Bucharest)*, **68**, no 12, 2017, p.3010-3014.
29. F.E. IONICA, L. MOGOANTA, S. NEGRES, L.E. BEJENARU, O.M. CRISTEA, O. BADEA, C. BEJENARU. Comparing the antifibrotic effect on the liver of Telmisartan and Pentoxifylline, in a Wistar rat experimental model. *Romanian Journal of Morphology and Embryology* 2017, 58(4):1237-1248.
30. CHRISTAKIS NA., FOWLER JH. The collective dynamics of smoking in a large social network. *N Engl J Med* 2008; 358: 2249-58.
31. CATERSON ID., HUBBARD V., BRAY GA., et al. Prevention Conference VII: Obesity, a Worldwide Epidemic Related to Heart Disease and Stroke: Group III: Worldwide Comorbidities of Obesity. *Circulation*, 2004;110(18):e476-e 483.
32. O.M. CRISTEA, C.S. AVRAMESCU, M. BALASOIU, F.D. POPESCU, F. POPESCU, M.O. AMZOIU. Urinary tract infection with Klebsiella pneumoniae in Patients with Chronic Kidney Disease. *Current Health Sciences Journal* 2017,43(2):137-148.
33. C. AVRAMESCU, V. BICIUSCA, T. DAIANU, A. TURCULEANU, M. BALASOIU, S. N. POPESCU, OANA IONETE, C. SIMIONESCU. Cytokine panel and histopathological aspects in the systemic lupus erythematosus. *Romanian Journal of Morphology and Embryology* 2010, 51(4):633-640.
34. ENE, C.G., ROSU, A., GHEORMAN, V., CALBOREAN, V., TENEA COJAN, T.S., ROGOVEANU, O.C., VLADU, M.I., RADU, L. Incidence of Osteoporosis and the Risk of Fracture in Patients with Rheumatoid Arthritis Undergoing Corticosteroid Treatment, *Rev. Chim. (Bucharest)*, **69**, no. 7, 2018, p.1851-1854.
35. LAVIE CJ., MILANI RV., VENTURA HO. Obesity and cardiovascular disease. Risk factors, paradox, and impact of weight loss. *J Am Coll Cardiol* 2009;53:1925-1932.
36. OSIAC E., BALSEANU T-A., CATALIN B. et al. Optical coherence tomography as a promising imaging tool for brain investigations. *Romanian Jurnal of Morphology and Embriology*. Volume 55 Issue 2, Supplement: S.2014. Pages 507-512.
37. ALMDAL T., SCHARLING H., JENSEN JS., VESTERGAARD H. The independent effect of type 2 diabetes mellitus on ischemic heart

- disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. *Arch Intern Med* 2004; 164:1422.
38. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *Circulation* 2002;106:3143
39. PUIU, I., DAN, A.O., TARTEA, E.A., ROGOVEANU, O.C., BICA, E.A., DINESCU, S.N., VASILE, R.C., DINESCU, V.C., ROMANESCU, F.M., TUDORASCU, D.R., Assessing Factors that influence the Level of Glycated Hemoglobin in Children and Adolescents with Type 1 Diabetes. *Rev. Chim. (Bucharest)*, **69**, no. 11, 2018, p.4233-4236.
40. RADU, L., CARSOTE, M., PREDESCU, A.M., TENEA-COJAN, T.S., SOCEA, B., BALEANU, V.D., POPESCU, M., IONOVICI, N., ALBULESCU, D.M., Biochemical parameters in patients using teriparatide *Rev.Chim.(Bucharest)* **69**, no.12, 2018, p. 3483-3485
41. B. SOCEA, L. RADU, D. CLENCIU, T. S. TENEA COJAN, V. BALEANU, C.G. ENE, S.R. GIRGAVU, I.M. VLADU, The Utility of Visceral Adiposity Index in Prediction of Metabolic Syndrome and Hypercholesterolemia, *Rev.Chim.(Bucharest)* **69**, no. 11, 2018, p. 3112-3114
42. CLENCIU, D., TENEA COJAN, T.S., DIJMARESCU, A.I., ENE, C.G., DAVITOIU, D.V., BALEANU, V.D., CIORA, C.A., SOCEA, B., VOICULESCU, D.I., NEDELUTA, R.E., CALBOREAN, V. GHEORMAN, V., VLADU, I.M., Diabetic retinopathy in relation with EGDR value in patients. *Rev Chim (Bucharest)*, **70**, no. 4, 2019, p. 1434-1438
43. VLADU, I.M., TENEA COJAN, T.S., DEMETRIAN, A., CRISTEA, O.M., ENE, C.G., CLENCIU, D., The Presence of Chronic Kidney Disease in Relation to Age and Duration of Diabetes Mellitus, *Rev Chim (Bucharest)*, **70**, no. 4, 2019, p. 1471-1475
44. VLADU, I.M., RADU, L., GIRGAVU, S.R., TENEA COJAN, T.S., ENE, C.G., CALBOREAN, V., GHEORMAN, V., CLENCIU, D. Alteration of Glucidic Metabolism in Relation with Visceral Adiposity Index, *Rev Chim (Bucharest)*, **69**, no 9, 2018, p.2479-2481.
45. ROSENGREN A., PERK J., DALLONGEVILLE J. Prevention of Cardiovascular Disease. In *ESC Textbook of Cardiovascular Medicine*, 2nd Ed; eds John Camm A, Luscher T, Serruys P 2009.

Manuscript received:19.12.2018